Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares Rise
Black Diamond Therapeutics (BDTX) reported Phase 2 results for Silevertinib, showing 60% ORR and 15.0-month mPFS in NSCLC patients. FDA supports Phase 3 trial. Q3 2026 net loss was $10.0M. Stock rose 7.20% on results. Company has $102.0M cash.
How this was made
The 30-second read
Why it matters
The data represent a material clinical milestone that could drive near‑term price movement and set the stage for future value creation.
Market read
First disclosure of positive Phase 2 data; likely to influence biotech sector sentiment and BDTX’s valuation.
What to watch
Potential competition from other EGFR inhibitors and the need for regulatory approval timelines.
Background
Black Diamond Therapeutics announced updated Phase 2 results for its NSCLC drug Silevertinib and outlined a regulatory path with the FDA for a Phase 3 trial.
Ticker impact
Black Diamond Therapeutics disclosed Phase 2 trial results for Silevertinib with 60% ORR and plans for a Phase 3 trial, a first report of this data.
likely upward pressure as investors price in the positive trial data and upcoming Phase 3 enrollment.
Phase 2 data are material for a biotech; no prior public release, and the company’s cash runway supports continued development.
Market effects
Positive NSCLC data may boost sentiment toward other EGFR‑targeted biotech firms.
Limited to U.S. biotech investors; no broader regional effect.
Modest; trial data could attract interest from global oncology investors.
Counterpoint
If Phase 3 enrollment is delayed or data do not replicate, the stock could face disappointment.
Key entities
- companyBlack Diamond Therapeutics, Inc.
Biotech company developing Silevertinib for NSCLC.
